Skip to main content
Fig. 4 | Journal of Neuroinflammation

Fig. 4

From: Circulating EZH2-positive T cells are decreased in multiple sclerosis patients

Fig. 4

EZH2 immunophenotyping in PBMC from multiple sclerosis patients and controls. a Graphs showing the percentage of EZH2-positive cells in T cells and CD56dim NK cells from healthy controls (HC; n = 13), untreated multiple sclerosis patients (UNT; n = 10), and the same cohort of patients after 1 year of natalizumab treatment (NTZ; n = 10). b, c Graphs showing EZH2 expression in different CD4+ and CD8+ T cell subsets (HC, n = 13; UNT, n = 10; NTZ, n = 10). Naïve T cells were defined as CD45RO−/CCR7+. Central memory (CM) T cells were defined as CD45RO+/CCR7+. Effector memory (EM) T cells were defined as CD45RO+/CCR7−. Terminally differentiated (TD) effector T cells were defined as CD45RO−/CCR7+. Gray boxes, EZH2-positive cells; open boxes, EZH2-negative cells. d Graphs showing the percentage of tumor necrosis factor (TNF)-α-positive cells in CD4+ and CD8+ T cells expressing EZH2 (HC, n = 7; UNT, n = 4; NTZ, n = 4). Gray boxes, EZH2-positive cells; open boxes, EZH2-negative cells. Statistics: a, b unpaired Student’s t test; c, d Mann-Whitney U test. *p values < 0.05; **p values < 0.01; ***p values < 0.001. EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit

Back to article page